★中英双语版我国药物经济学评价指南。 ★践行“健康中国”,中英双语版填补我国药物评价学空白,构建全球药物经济学评价领域的中国标准和中国话语权。 ★全国医疗保障系统、医疗保险管理部门、药品价格管理部门、基本药物政策管理部门、新药审评部门、各类药业企业等的常备书。 ★第十、十一届全国入大常#委会副委员长,第十二届全国政协副主席,中国科学技术协会原主席韩启德院士;第十一届全国入大常#委会副委员长桑国卫院士;美国塔夫茨大学健康价值与风险评估中心主任,国际药物经济学会(ISPOR)2005-2006届主席Peter J. Neumann教授;日本东京大学公共政策研究院卫生政策与技术评估教授,国际药物经济学会(ISPOR)候任主席(2021-2022)sao Kamae教授等四位国内外权#威专家联袂推荐。 ★主编刘国恩教授,为我国药物经济学的创始人,世界著#名药物经济学家,现任中国药物经济学专业委员会主任委员,曾担任国际医药经济学会亚太联合会主席。 ★本书作者团队囊括了中国药学会、国家卫生健康委、国家发展改革委、国#务院发展研究中心、国#务院参事室、中国科技协会、国家自然科学基金委员会、中国医师协会、中国非处方药物协会、中国劳动和社会保障科学研究院、中国人民解放军战略支援部队,以及北京大学、复旦大学、天津大学、华中科技大学、中国药科大学、首都医科大学、第二军医大学、海军军医大学、新加坡国立大学、北京协和医院、解放军301医院等单位的一#流专家学者。
卫生技术评估是我国医疗、医保、医药事业改革与发展科学决策的重要基础。该指南既提供基本理论,又紧密结合我国实际,是药物经济学评价的基础读本。 Health technology assessment provides an important foundation for the scientific decision-making during the reform and development of China's health care, health insurance, and pharmaceutical industry. The Guidelines not only provide fundamental theories, but also closely integrate the real-world practice in China. It is an essential guide for pharmacoeconomic evaluation.
————韩启德院士,第十二届全国政协副主席,中国科学技术协会原主席 Han Qide, Member, 12th National Committee of the Chinese People's Political Consultative Conference, Chinese Academy of Science Former President of the Chinese Association for Science and Technology
感谢国内外专家团队的共同努力,使该指南能够成为中国目前wei一的药物经济学评价指南,并首#次出版中英双语版,与欧美发达国家的指南标准高度接轨。衷心期待新指南的应用,将进一步科学助推国家医改,为完善国家医保目录、促进合理用药,提高医药卫生资源的配置效率发挥更好作用。 Thanks to the effort of a team of national and international experts, leading to the only guidelines available for pharmacoeconomic evaluations in China and well consistent with the guidelines in developed countries. In addition, this is the first time that we have our own guidelines in both Chinese and English versions. I sincerely look forward to the application of these latest guidelines, which, I believe, will further facilitate the national healthcare reform and play an instrumental role in improving the national reimbursement drug list, promoting rational use of drugs, and increasing the efficiency of healthcare resource allocation.
——桑国卫院士,第十一屆全国入大常#委会副委员长 Sang Guowei, Member, Chinese Academy of Engineering Vice Chairman of the 11th Standing Committee of National People's Congress
非常高兴看到《中国药物经济学评价指南(2020中英双语版)》的正式发布。药物经济学指南正在为世界各国支付方制定科学、循证决策提供有力支持,促进卫生支出获得更多价值。该新版指南必将更好帮助中国政策制定者深化卫生改革,进一步提高国民健康水ping。 It is great to see the publication of the China Guidelines on Pharmacoeconomic Evaluations. Pharmacoeconomic guidelines are helping payers around the world as they seek to make informed, evidence-based decisions to obtain better value for their health spending. These new guidelines should help policy makers in China as they undertake reforms to further population health.
——Peter J. Neumann, 美国塔夫茨大学健康价值与风险评估中心主任; 国际药物经济学会(ISPOR)2005-2006届主席 Director, Center for the Evaluation of Value and Risk in Health at Tufts University; 2005-2006 President of ISPOR
该版指南的一大特色是提供了中、英双语版本,这不仅受众于中国读者,对国际读者来说也十分有益。同时,除了成本-效果分析这一标准内容外,此版指南还纳入了诸如公ping性、预算影响分析等更为广泛的内容。我相信《中国药物经济学评价指南》会为全球药物经济学领域注入强大力量。 A distinguished feature for this edition is its bilingual setting in Chinese and English, which is served not only to Chinese affiliates, but also quite useful to international readers. Since it also includes extensive issues such as ‘equity’ or budget impact analysis’ in addition to the standard of cost-effectiveness analysis, I believe it must be a significant input to the pharmacoeconomic communities in the world.
——Isao Kamae, 日本东京大学公共政策研究院卫生政策与技术评估教授; 国际药物经济学会(ISPOR)候任主席(2021-2022) Director of Health Policy and Technology Assessment at University of Tokyo; President-elect of ISPOR (2021-2022)
以下为对购买帮助不大的评价